VivoSeq
Other

Opioid Withdrawal

0

Pipeline Programs↗

7

Active Trials↗

3

Companies Involved↗

Opioid Withdrawal is an early-stage landscape with 0 programs across 3 companies. The most active players are BioCorRx Pharmaceuticals Inc, atai Therapeutics, Inc., BioXcel Therapeutics Inc.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

85/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

B

BioCorRx Pharmaceuticals Inc

0 programs

PreclinicalA

atai Therapeutics, Inc.

0 programs

PreclinicalB

BioXcel Therapeutics Inc

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

27

clinical trials

Completed17 · 63%
Recruiting4 · 15%
Active, not recruiting3 · 11%
Terminated2 · 7%
Withdrawn1 · 4%

Clinical Trials

Trial Activity

27 trials

Assessing a Clinically-meaningful Opioid Withdrawal Phenotype
Recruiting·UUniversity of Maryland, Baltimore·Phase 2·NCT05027919·60 enrolled
Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal
Recruiting·UUniversity of Pennsylvania·Phase 2·NCT05995535·150 enrolled
Novel Use of Probenecid to Alleviate Symptoms of Opioid Withdrawal
Recruiting·UUniversity of Calgary·Phase 2·NCT04939623·40 enrolled
Understanding the Mechanistic, Neurophysiological, and Antinociceptive Effects of Transcutaneous Auricular Neurostimulation for Treatment of Chronic Pain
Recruiting·TThe University of Texas Medical Branch, Galveston·Preclinical·NCT05555485·60 enrolled
Pharmacokinetic and Safety Study of Oral Lofexidine in Neonates Experiencing Opioid Withdrawal Due to Intrauterine Exposure to Opioids
Active, not recruiting·BBioCorRx Pharmaceuticals Inc·Phase 2·NCT06047834·24 enrolled
Evaluating Buspirone to Treat Opioid Withdrawal
Active, not recruiting·JJohns Hopkins University·Phase 2·NCT05511909·100 enrolled
Sublingual Dexmedetomidine for Treating Opioid Withdrawal
Active, not recruiting·NNew York State Psychiatric Institute·Phase 1/2·NCT05712707·160 enrolled
Phase IIa Study of AV411, a Glial Activation Inhibitor, for Opioid Withdrawal
Completed·NNew York State Psychiatric Institute·Phase 2·NCT00723177·30 enrolled
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Completed·UUSWM, LLC (dba US WorldMeds)·Phase 3·NCT01863186·603 enrolled
Efficacy of Extended Release Tramadol for Treating Prescription Opioid Withdrawal
Completed·—·Phase 2/3·NCT00980044·53 enrolled
Palonosetron and Hydroxyzine to Reduce Opioid Withdrawal
Completed·SStanford University·N/A·NCT00661674·10 enrolled
Biased Opioid Agonists for Treatment of Opioid Withdrawal in OUD
Completed·National Institute on Drug Abuse (NIDA)·Phase 2·NCT04316559·5 enrolled
5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence
Completed·SStanford University·N/A·NCT01549652·133 enrolled
Tramadol to Reduce Opioid Withdrawal Symptoms
Completed·National Institute on Drug Abuse (NIDA)·Phase 2·NCT00142896·16 enrolled
Combining Pregabalin (LYRICA®) With Lofexidine (LUCEMYRATM) to Treat OPIOID Withdrawal
Completed·UUniversity of Pennsylvania·Phase 2·NCT04218240·90 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)